StudyFinder

MAYFLOWERS-0B-20: A Prospective Study Evaluating Maternal and FetaL Outcomes in the ERa of ModulatorS (MAYFLOWERS)

Recruiting

This study is being done to look at how pregnancy affects the health of women with cystic fibrosis (CF) and to look at the health of babies born to women with CF. It is expected that most but not all women will be taking the newest CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulator medication called TRIKAFTA®. It is not known how this medication will affect the health of mother and infant.

I'm interested

Female
16 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 16 years old
• pregnant, intending to continue pregnancy
• enrolled in the Cystic Fibrosis Foundation Patient Registry (CFFPR)
Exclusion Criteria:

• none

Rare Diseases, Respiratory System

Clinics and Surgery Center (CSC), Cystic Fibrosis, Pregnancy

Mary Bailey - mpbailey@umn.edu
Joanne Billings
SITE00001209
See this study on ClinicalTrials.gov

Back